N-methylpiperazine

COC(=O)c1ccc(OCc2ncccc2N2CCN(C)CC2)cc1

Ausbeute 64.2%750 AstraZeneca ELN dataset

CC(=O)Nc1cnc(N2CCN(C)CC2)cn1

Ausbeute 79.5%750 AstraZeneca ELN dataset

CN1CCN(c2ccc(O)cc2)CC1

Ausbeute 51.0%750 AstraZeneca ELN dataset

CN1CCN(c2cncc(Br)c2)CC1

Ausbeute 21.3%750 AstraZeneca ELN dataset

CN1CCN(c2nc(Br)nn2C)CC1

Ausbeute 0.0%750 AstraZeneca ELN dataset

CCOC(=O)c1cnc2cc(OC)c(N3CCN(C)CC3)cc2c1Nc1ccc(Cl)cc1Cl

Ausbeute 0.0%750 AstraZeneca ELN dataset

CCOC(=O)c1cnc2ccc(N3CCN(C)CC3)cc2c1Nc1ccc(F)cc1F

Ausbeute 0.0%750 AstraZeneca ELN dataset

Cc1ccc(-c2ncc[nH]2)cc1NC(=O)c1ccc(OCc2ncccc2N2CCN(C)CC2)cc1

Ausbeute 0.0%750 AstraZeneca ELN dataset

COc1cc(N2CCN(C)CC2)cc([N+](=O)[O-])c1

Ausbeute 71.2%750 AstraZeneca ELN dataset

COc1cc(Cl)ccc1N1CCN(C)CC1

Ausbeute 63.6%750 AstraZeneca ELN dataset

COc1cc(Cl)ccc1N1CCN(C)CC1

Ausbeute 0.0%750 AstraZeneca ELN dataset

COC(=O)c1cc(N2CCN(C)CC2)cc([N+](=O)[O-])c1

Ausbeute 65.2%750 AstraZeneca ELN dataset

CN1CCN(c2nc(Cc3ccc(F)cc3)ncc2F)CC1

Ausbeute 96.9%DOI: 10.6084/m9.figshare.5104873.v1uspto-grants-1998_03

CCOC(=O)c1ccc2cc(N3CCN(C)CC3)ccn2c1=O

Ausbeute 106.8%DOI: 10.6084/m9.figshare.5104873.v1uspto-grants-1998_03

CCOC(=O)c1cc(CC)c2cc(N3CCN(C)CC3)ccn2c1=O

Ausbeute 99.9%DOI: 10.6084/m9.figshare.5104873.v1uspto-grants-1998_03

CCOC(=O)c1cc(NC)c2cc(N3CCN(C)CC3)c(F)cn2c1=O

DOI: 10.6084/m9.figshare.5104873.v1uspto-grants-1998_03

CCOC(=O)c1cc(CC)c2c(F)c(N3CCN(C)CC3)c(F)c(F)n2c1=O

DOI: 10.6084/m9.figshare.5104873.v1uspto-grants-1998_03

Cc1cc2c3c(c1)N=C(N1CCN(C)CC1)c1ccccc1N3CC2

DOI: 10.6084/m9.figshare.5104873.v1uspto-grants-1988_02

CN1CCN(C(=O)Nc2ccccc2N2CCc3cc(Br)ccc32)CC1

Ausbeute 90.0%DOI: 10.6084/m9.figshare.5104873.v1uspto-grants-1988_02

$CN1CCN(C(=O)Nc2ccccc2N2CCCc3cc(Br)ccc32)CC1.O=C(O)/C=C\C(=O)O$

Ausbeute 61.0%DOI: 10.6084/m9.figshare.5104873.v1uspto-grants-1988_02

Seite 1Weiter